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Abstract
Mutations in the GALNT3 gene result in familial tumoral calcinosis, characterized by persistent
hyperphosphatemia and ectopic calcific masses in soft tissues. Since calcific masses often recur
after surgical removal, a more permanent solution to the problem is required. Nicotinamide is
reported to lower serum phosphate by decreasing sodium-dependent phosphate co-transporters in
the gut and kidney. However, its effectiveness in tumoral calcinosis remains unknown. In this
study, we investigated nicotinamide as a potential therapy for tumoral calcinosis, using a murine
model of the disease–Galnt3 knockout mice. Initially, five different doses of nicotinamide were
given to normal heterozygous mice intraperitoneally or orally. Treatment had no effect on serum
phosphate levels; however, serum levels of a phosphaturic hormone, fibroblast growth factor 23
(Fgf23), decreased in a dose-dependent manner. Subsequently, high-dose nicotinamide (40 mM)
was tested in Galnt3 knockout mice fed a high phosphate diet. The radiographic data pre- and
post-treatment showed that nicotinamide did not reverse the calcification. However, the treatment
retarded calcification growth after four weeks, while in the untreated animals, calcifications
increased in size. The therapy did not affect serum phosphate levels, but intact Fgf23 decreased in
the treated mice. The treated mice also had increased calcium in the heart. In summary,
nicotinamide did not alter serum phosphate levels, likely due to compensatory decrease in Fgf23
to counteract the phosphate lowering effect of nicotinamide. Although increased calcium
accumulation in the heart is a concern, the therapy appears to slow down the progression of
ectopic calcifications.
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Introduction
Familial tumoral calcinosis is characterized by hyperphosphatemia and inappropriately
normal or elevated 1,25-dihydroxyvitamin D [1,25(OH)2D], leading to ectopic calcifications
in soft tissues. The genetic cause of this disease is a biallelic mutation in either of the three
genes: GALNT3 [1–3], KL [4], or FGF23 [5, 6]. However, the majority of the patients have
mutations in GALNT3 [2]. GALNT3 encodes a glycosyltransferase, GalNAc transferase 3,
which O-glycosylates a phosphaturic hormone, fibroblast growth factor 23 (FGF23) to allow
secretion of intact FGF23 [7]. Secreted FGF23 will form a complex with fibroblast growth
factor receptors and co-receptor, Klotho, in the kidney [8, 9], to promote phosphate
excretion and inhibit 1,25(OH)2D biosynthesis [10]. Therefore, compromising any of the
three proteins jeopardizes proper renal phosphate excretion and 1,25(OH)2D synthesis.
Inactivating GALNT3 and FGF23 mutations render FGF23 proteins susceptible to
proteolysis by subtilisin-like proprotein convertases, and most FGF23 proteins are cleaved
into inactive fragments before secretion, leading to low or undetectable intact FGF23 despite
increased FGF23 production [7, 11–13]. This decrease in biologically active intact FGF23
results in increased phosphate reabsorption in the kidney and persistent hyperphosphatemia.
Furthermore, low intact FGF23 increases biosynthesis of 1,25(OH)2D and decreases its
metabolism, which enhance phosphate and calcium absorption in the small intestine. Thus,
this inability to produce sufficient intact FGF23 is the main molecular defect responsible for
increased phosphate reabsorption and calcium/phosphate absorption, ultimately leading to
ectopic calcifications.
The most common treatment of tumoral calcinosis is surgical resection of recurring massive
calcifications. Previously described therapies include dietary phosphate restriction,
phosphate binders, and drugs that are thought to be phosphaturic, but these treatments are
only limited to single case reports or anecdotes [14–16]. One of those drugs is nicotinamide
(also known as niacinamide), which reduces phosphate (re)absorption by decreasing activity
of sodium-dependent phosphate co-transporters in both intestine [17, 18] and kidney [19,
20]. In recent clinical trials, nicotinamide and other niacin derivatives, which block sodium-
phosphate co-transport, have seen success in treatment of hyperphosphatemia in patients
undergoing dialysis [21–24]. Nicotinamide has been tested in one tumoral calcinosis patient
[14]; however, due to the scarcity of patients, its effectiveness in this disorder is still
unknown. Therefore, we used a murine model of tumoral calcinosis, Galnt3 knockout mice
[25], to assess the effect of nicotinamide therapy for tumoral calcinosis.
Materials and Methods
Generation of Experimental Mice
All experimental mice used in this study were in the C57BL/6 background. Since males
homozygous for a Galnt3 mutation are sterile [25, 26], a heterozygous male and
homozygous female were bred to generate experimental mice. Heterozygous mice are
phenotypically normal [25], and thus, used in lieu of wild-type mice for nicotinamide dosing
study. Homozygous mice were used for a long-term nicotinamide treatment. The study was
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approved by the Indiana University School of Medicine Institutional Animal Care and Use
Committee.
Dose Finding in Heterozygous Mice
Nicotinamide (doses 0, 2.5, 5, 7.5, and 10 mmol/kg/day) was administered to six-week-old
male and female heterozygotes each day for three consecutive days via intraperitoneal
injection. Serum and plasma samples were collected via cardiac puncture one day after the
third injection. Heterozygous female mice were also placed on a nicotinamide/acidified
water drink mix (0, 10.4, 20.8, 31.3, and 41.7 mM; ad libitum). These doses are equivalent
of those used in the injections, assuming that mice weighed 25 g and consumed 6 mL per
day [27]. For simplicity, the doses are presented as 0, 10, 20, 30, and 40 mM, respectively.
The treatment started when the mice were 8 weeks old and lasted for two weeks. Terminal
blood samples were collected via cardiac puncture under anesthesia. Mice were fed Teklad
Global 18% Protein Extruded Rodent Diet (2018SX, Harlan Laboratories, Madison WI),
which contained 1.01% calcium, 0.65% phosphorus, and 2.05 IU/g vitamin D3.
Nicotinamide Treatment in a Murine Model of Familial Tumoral Calcinosis
To induce ectopic calcifications, male and female Galnt3 knockout mice were placed on a
high phosphate diet from weaning at four weeks of age [28]. The high phosphate diet
contained 1.65% phosphorus, 1.0% calcium, 2.0 IU/g vitamin D3 (TD.88345, Harlan). After
10 weeks on the diet, a pre-treatment x-ray was taken of lateral and prone positions, using a
piXarray 100 Digital Specimen Radiography System with BioPix software. Image
acquisition was performed at 24-kV voltage and 0.4 sec exposure time. The mice were then
given either acidified water or nicotinamide/acidified water drink mix (40 mM; ad libitum).
After four weeks on the treatment, a post-treatment x-ray of the mice was taken and blood
and urine samples were collected.
Kidneys and hearts were also collected to determine phosphate and calcium content. To
extract phosphate and calcium, the tissues were minced and submerged in 0.6N HCl solution
(2.5 μL per mg of tissue) for three days under constant, gentle mixing. The supernatant after
centrifugation was used for biochemical analysis.
Biochemical Analyses
Serum, urine, kidney supernatant and heart supernatant were measured using an RX
Daytona clinical chemistry analyzer (Randox Laboratories, Crumlin, UK). Parathyroid
hormone (PTH) was measured using Mouse PTH 1-84 ELISA kit (Immutopics
International, San Clemente, CA). Intact Fgf23 was measured using an Intact Fgf-23 ELISA
kit (Kainos Laboratories, Tokyo, Japan). Total Fgf23 levels (intact and C-terminal
fragments) were measured, using Mouse FGF-23 (C-Terminal) ELISA kit (Immutopics
International).
Statistical Analyses
Mean and standard error of the mean were calculated for all outcomes according to dosage
and sex. Nicotinamide dosing in heterozygous mice were analyzed using ANOVA.
Nicotinamide treatment in Galnt3 knockout mice were analyzed using unpaired, two tailed t-
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test between treated mice and same-sex untreated mice. P-values ≤0.05 were considered
significant.
Results
Dosing Study
Phenotypically normal heterozygous mice were injected with different doses of
nicotinamide for three consecutive days. Nicotinamide reduced intact Fgf23 levels
(p=0.050) without changing serum phosphorus concentration (data not shown). However, at
the higher doses, the animals become inactive and less alert. Therefore, nicotinamide was
administered orally mixed in drinking water. In contrast to the i.p. injection, the mice on this
treatment remained active and alert regardless of the dose. Body weights of the mice after
the treatment were not different between the five groups (data not shown). Despite no
change in serum phosphorus, continual nicotinamide decreased intact and total Fgf23
concentrations (p=0.021 for intact, p<0.001 for total), indicating down-regulation of Fgf23
as a result of the treatment (Figure 1). Serum PTH was generally lower in mice treated with
nicotinamide, but there was no statistically significant difference. Although statistically not
significant, urinary phosphate excretion (urinary phosphorus/urinary creatinine ratio) was
lower in the animals receiving higher doses. These data suggest that the mice achieved
phosphate homeostasis by increasing phosphate reabsorption in the kidney to counter the
known phosphate lowering effect of nicotinamide in the gut [17, 18] and kidney [19, 20].
Nicotinamide Treatment of a Murine Model of Familial Tumoral Calcinosis
To induce ectopic calcifications, Galnt3 knockout mice were fed the high phosphate diet for
10 weeks. Given the higher phosphate content of the diet, we utilized the highest dose tested
in the heterozygous mice (40 mM) for treatment of this animal model. As expected, serum
phosphorus in Galnt3 knockout mice was higher than that in heterozygotes in the dosing
study. In an attempt to produce more intact Fgf23 in the face of increased proteolysis,
Galnt3 knockout mice also produced markedly higher total Fgf23, compared to
heterozygous mice. Similar to the dosing study, serum phosphate did not differ greatly
between control and treated groups, and no gender difference was observed (Figure 2).
Urine phosphate (and calcium) in the treated mice showed a trending increase, despite lower
intact Fgf23 levels, but neither males nor females reached statistical significance.
Nicotinamide treatment did not affect serum PTH levels although treated males had slightly
lower PTH than untreated. However, it lowered intact Fgf23 dramatically in both males and
females (males, p=0.041; females, p<0.001), comparable to the effect observed in
heterozygotes.
Nicotinamide treatment slightly reduced total Fgf23 levels only in treated males. Serum
alkaline phosphatase was markedly elevated in treated female mice (p< 10−6), while treated
males maintained their alkaline phosphatase. Blood urine nitrogen (BUN) was significantly
higher only in treated females. Female mice on the treatment also experienced a significant
drop in weight (~11%), while male mouse weight dipped only slightly (data not shown).
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At the start of the treatment, the high phosphate diet induced ectopic calcifications visible on
radiographs, reminiscent of tumoral calcinosis, in four mutant mice. Two were treated with
nicotinamide, and the other two were not treated. Although the treatment did not eliminate
calcifications, radiographs showed no apparent increase in calcification sizes in the treated
mice (Figure 3). In contrast, the calcifications in the untreated mice became visibly larger.
Furthermore, one additional mouse developed calcification in the tongue when it remained
on the high phosphate diet without treatment, whereas the number of mice with
calcifications did not change for the treated group.
To determine whether accumulated calcium-phosphate products were released from
extraskeletal tissues, we measured calcium and phosphate levels in the heart and kidney.
Phosphate in treated groups paralleled the control groups, but a dramatic increase was seen
in heart tissue calcium, reaching statistical significance in females (p<0.01) (Figure 4). The
same trend was also seen in males, despite a smaller sample size (p=0.13).
Discussion
Nicotinamide (and other niacin derivatives) suppresses sodium-phosphate cotransport in the
gut [17, 18] and kidney [19, 20]. Given the physiologic effect of nicotinamide, it is a
potential therapy for familial tumoral calcinosis. However, due to insufficient observations
in humans, the effectiveness of nicotinamide in tumoral calcinosis remains unclear. To test
this potential treatment, we used a murine model of this disorder. Regardless of genotypes or
delivery route, nicotinamide significantly decreased serum Fgf23 concentrations. Since
nicotinamide reduces intestinal absorption and/or renal reabsorption, it would likely limit
cellular uptake of phosphate by osteocytes, the source of Fgf23. As a result of this
compensatory response to nicotinamide, the treatment had no net effect on serum phosphate
levels. Similarly, one tumoral calcinosis patient treated with nicotinamide had increased
phosphate excretion, accompanied by lower Fgf23 [14]. This normal response to changing
phosphate likely reduces the efficacy of nicotinamide as a therapy in blocking the sodium
phosphate transport.
Although serum phosphate was unchanged in heterozygous mice, nicotinamide treatment in
the murine model of tumoral calcinosis was pursued because these animals may respond
differently due to their inability to make sufficient intact Fgf23. Similar to the heterozygous
mice, high-dose nicotinamide treatment reduced intact Fgf23, resulting in no net change in
serum phosphate. However, in contrast to decreased phosphate excretion in heterozygous
mice at the high doses, Galnt3 knockout mice had a trend for increased urinary phosphate
excretion. These data suggest that the mutant mice may be maximally reabsorbing phosphate
by lowering intact Fgf23, but excess phosphate (and calcium) presumably released from the
extraskeletal tissues are still excreted in urine. We cannot exclude the possibility that the
higher phosphate load in Galnt3 knockout mice led to increased urinary phosphate
excretion.
In tumoral calcinosis, persistent hyperphosphatemia results in ectopic calcifications in soft
tissues. Comparison of pre- and post- treatment radiographs showed that nicotinamide may
not clear calcifications, but likely slow down calcification progression and prevent further
Reilly et al. Page 5
Bone. Author manuscript; available in PMC 2015 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
calcification from occurring. After ten weeks of depositing phosphate into tissues, four
weeks of treatment may have been insufficient for completely resolving the calcifications.
Alternatively, once formed, the calcification may not be able to be lysed. It is also possible
that the high phosphate diet was too much to overcome with the dose used in this study.
Although nicotinamide could not eliminate calcifications, increasing urinary excretion and
slowing of calcification process suggests nicotinamide may be effective in the treatment of
tumoral calcinosis. However, while the treatment did not alter phosphate content in the
kidneys and hearts, an unexpected rise in heart tissue calcium is a concern. The
physiological consequences of elevated heart calcium are uncertain, but it likely has
negative implications for cardiovascular health [29]. The finding is relevant to other studies
using nicotinamide to control hyperphosphatemia, particularly clinical trials for
hemodialysis patients. However, in the general population, niacin appears to have cardio-
protective effects [30]. Use of niacin has led to reduced cardiovascular events, not increased
events which would be expected if the increased calcification was pathologic. We have no
explanation for this unexpected observation, especially since phosphate content of the tissue
was not simultaneously increased, suggesting that the calcium may have deposited with
other anions. Further studies are required to discern the mechanism and consequences of
such a finding.
In general, nicotinamide had greater impact on female Galnt3 knockout mice. Serum
alkaline phosphatase was markedly higher in treated females, compared to males. Galnt3
knockout mice have lower alkaline phosphatase [25, 26], but nicotinamide essentially
normalized alkaline phosphatase in the treated females, possibly as an early sign of
improving serum phosphorus. The increment in BUN was only significant in treated
females. Female mice on the treatment also lost body weight, while the drug had no effect
on weight of males. Since water consumption is expected to be proportional to body size
with no gender effect, it is possible that nicotinamide is metabolized at the different rates
between males and females and has higher potency in females.
Conclusion
Heterozygous mice administered with nicotinamide experienced a significant decrease in
Fgf23 to compensate for suppression of phosphate absorption in the gut and reabsorption in
the kidney by nicotinamide. Similarly, Galnt3 knockout mice lowered Fgf23, which
perpetuated the hyperphosphatemic phenotype and failed to remove ectopic calcifications.
Although this compensatory reduction in Fgf23 reduces the effectiveness of nicotinamide,
the radiographic evidence suggests that nicotinamide may retard calcification progress.
Increased heart calcium due to the treatment is concerning. However, nicotinamide remains
a viable treatment option for mild tumoral calcinosis. Clinical studies are needed to confirm
the translational potential of these findings.
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Highlights
• Oral nicotinamide did not alter serum phosphate; however, it reduced serum
Fgf23 concentrations.
• Although nicotinamide treatment did not remove ectopic calcification, it appears
to retard progression of calcification.
• Galnt3 knockout mice treated with nicotinamide had significantly higher
calcium in the heart.
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Figure 1.
Administration of nicotinamide in drinking water. Nicotinamide was infused in drinking
water to treat heterozygous females. While nicotinamide did not change serum phosphorus,
it had a significant effect on serum Fgf23 levels. Each column represents the mean ± SEM.
N = 8–12 for serum measurements; N = 3–6 for urine measurements. ANOVA p-values
between the five groups are shown above each graph. N.S., not significant; Ca, calcium; Pi,
phosphorus; ALP, alkaline phosphatase; BUN, blood urine nitrogen; Ur, urine; Cr,
creatinine.
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Figure 2.
Nicotinamide treatment of Galnt3 knockout mice. Galnt3 knockout mice were fed a high
phosphate diet for 10 weeks, followed by 4 weeks on nicotinamide infused drinking water.
Intact Fgf23 decreased significantly in treated males and females; however, total Fgf23
decreased only in males. Each column represents the mean ± SEM. N=8–12 for serum
measurements, N=5–8 for urine measurements. T-test P < 0.05* and P < 0.01***, compared
to sex-matched controls. Ca, calcium; Pi, phosphorus; ALP, alkaline phosphatase; BUN,
blood urine nitrogen; Ur, urine; Cr, creatinine.
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Figure 3.
Effect of nicotinamide on ectopic calcifications in Galnt3 knockout mice. After ten weeks of
the high phosphate diet, four Galnt3 knockout mice developed well-defined ectopic
calcifications (white arrows). Two were treated with approximately 40 mM of nicotinamide,
and the other two were untreated. While calcifications in the untreated mice (Untreated 1
and 2) became larger, more radiodense, or interconnected, there was no clear increase in the
calcification sizes in the treated mice (Treated 1 and 2). Furthermore, an additional untreated
mouse (Untreated 3) developed calcification in the tongue, which was not apparent in the
pre-treatment radiograph.
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Figure 4.
Effects of nicotinamide treatment on kidney and heart tissues in Galnt3 knockout mice.
Calcium and phosphorus in the kidney were not affected; however, calcium in the heart was
significantly higher in the treated females. Each column represents the mean ± SEM. N=7–
12 for kidney measures and N=4–9 in heart measures. T-test P< 0.01***, compared to same-
sex control group.
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